Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jul 22, 2010


Title: Oligomeric Compounds and Compositions for Use in Modulation of Pri-miRNAs

Patent Number: 7,759,319

Filed: Jan. 10, 2006

Lead Inventor: Bridget Lollo, Regulus Therapeutics

The patent, its abstract states, claims "compounds, compositions, and methods … for modulating the levels, expression, processing, and function of pri-miRNAs. In particular, methods and compounds are provided for the modulation of the levels, expression, processing, or function of polycistronic pri-miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and pri-miRNAs.

"Further provided are methods for selectively modulating pri-miRNA levels in a cell," the abstract adds. "Also provided are methods for identifying oligomeric compounds that result in increased pri-miRNA levels when contacted with a cell."

Title: Compositions and Methods for Inhibiting Gene Expression of a Gene from the Ebola

Patent Number: 7,759,320

Filed: March 25, 2008

Lead Inventor: Sina Bavari, Alnylam Pharmaceuticals

"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the Ebola virus," the patent's abstract states.

Title: RNA Interference Pathway Genes as Tools for Targeted Genetic Interference

Patent Number: 7,759,463

Filed: Feb. 22, 2007

Lead Inventor: Craig Mello, University of Massachusetts

"Genes involved in double-stranded RNA interference are identified and used to investigate the RNAi pathway," according to the patent's abstract. "The genes and their products are also useful for modulating RNAi pathway activity."

Title: Bioinformatically Detectable Viral Regulatory Genes

Patent Number: 7,759,478

Filed: Aug. 29, 2003

Inventor: Isaac Bentwich, Rosetta Genomics

The invention, the patent's abstract states, "relates to a group of novel viral RNA regulatory genes, here identified as viral genomic address messenger genes or VGAM genes, and as genomic record or GR genes.

"VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism," it states. "GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing, and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity."

Title: Modified iRNA Agents

Patent Number: 20100179309

Filed: Nov. 16, 2009

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

"The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose," the patent application's abstract states. "The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, [for instance] by using the non-ribose moiety as a point to which a ligand or other entity … optionally substituted with at least one carbohydrate [and] directly or indirectly tethered. The invention also relates to methods of making and using such modified iRNA agents."

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.